The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Sean Duffy, identified as a director and officer of Omada Health, Inc. (OMDA), reports a proposed sale of 12,944 common shares, with an aggregate market value of $240,499.52. The notice lists 12,944 shares acquired through stock-option exercise on November 4, 2026, and gives March 13, 2026, as the adoption date for the Rule 10b5-1 plan.
Omada Health, Inc. (OMDA) is named in an amended beneficial-ownership report submitted by the reporting persons: Revelation Alpine, LLC; Revelation Alpine, L.P.; Revelation Alpine GP, LLC; Revelation Healthcare Fund II, L.P.; Revelation Healthcare Fund II GP, L.P.; Revelation Healthcare Fund II GP, LLC; Revelation Healthcare Fund IV, L.P.; Revelation Healthcare Fund IV GP, L.P.; Revelation Healthcare Fund IV GP, LLC; Michael Boggs; and Scott Halsted. As of September 30, 2026, none of the reporting persons may be deemed to beneficially own Omada common stock. The reported ownership percentage was 0.0%.
For Omada Health, Inc. common stock, BlackRock, Inc. reported beneficial ownership of 3,667,682 shares, or 6.0% of the class, as of September 30, 2026. BlackRock reported sole voting power over 3,586,364 shares and sole dispositive power over 3,667,682 shares, with no shared voting or dispositive power.
The reported position reflects securities attributed to specified BlackRock business units and subsidiaries or affiliates; it excludes securities attributed to other business units whose ownership is disaggregated. BlackRock said various persons may direct dividends or sale proceeds, but no one person's interest exceeded 5% of Omada's outstanding common shares.
Omada Health, Inc. director Jonathan D. Root received a grant of 694 restricted stock units on October 5, 2026, under the Non-Employee Director Compensation Program in lieu of retainer fees. Each unit represents the right to receive one share of common stock, with settlement on a date selected by Root under the Program or as otherwise provided by it. The reported direct share position following the grant was 192,571 shares.
Julie D. Klapstein, a director of Omada Health, acquired 549 restricted stock units on October 5, 2026, under the Non-Employee Director Compensation Program in lieu of retainer fees. Each RSU represents the right to receive one share of common stock, with settlement on a date she selects under the Program or as otherwise provided by it. The reported total following the transaction was 22,514 shares.
Omada Health, Inc. director Trevor Fetter was granted 751 restricted stock units (RSUs) on October 5, 2026, under the Non-Employee Director Compensation Program in lieu of retainer fees. Each RSU represents the right to receive one common share, with settlement on a date Fetter selects under the program or as otherwise provided by the program. As of October 5, 2026, Fetter held 25,172 common shares directly; a family trust of which he is trustee and beneficiary held 111,200 shares indirectly.
Jeryl L. Hilleman, a director of Omada Health, acquired 1,214 restricted stock units on October 5, 2026, under the Non-Employee Director Compensation Program in lieu of retainer fees. Each unit represents the right to receive one share of common stock. Settlement is to occur on a date selected by Hilleman under the Program or as otherwise provided by the Program. Hilleman’s reported direct holdings following the transaction were 27,869 shares.
Omada Health, Inc. Chief Executive Officer Sean P. Duffy exercised options for 12,944 shares at $5.82 and 4,314 shares at $8.28 on October 1, 2026, acquiring those amounts of common stock and selling them the same day. He sold 12,944 shares at a weighted-average price of $20.6082 and 4,314 shares at $20.90. The common-stock acquisitions and sales were made under a Rule 10b5-1 trading plan adopted March 13, 2026. A separate indirect holding of 851,659 shares is held in family trusts; Duffy disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. director and officer Sean Duffy gave notice of a proposed sale of 17,258 common shares, listed at an aggregate market value of $269,364.64. The notice lists October 1, 2026, as the approximate sale date and NASDAQ as the exchange. It also lists a 12,944-share acquisition from the issuer through exercise of stock options on October 1, 2026, with cash payment, and earlier transactions labeled 10b5-1 sales.
Omada Health, Inc. (OMDA) reported that Chief Executive Officer and director Sean P. Duffy sold a total of 14,960 shares of common stock on September 10, 2026 in open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026. The filing also reports 851,659 shares of common stock held indirectly in family trusts for the benefit of his family members, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.